Apellis Pharmaceuticals, Inc. APLS
Set alert
41.03 USD 0.00 0.00%
At close · May 15
41.06 +0.03 +0.07%
After hours · May 15, 4:00 PM ET
41.03 Day range 41.05
16.83 52-week range 41.14
- YTD
- +63.34%
- 1 year
- +150.79%
- Open
- 41.05
- Prev close
- 41.03
- Mkt cap
- 5.25B
- Vol
- 28.64M
- Avg vol
- 7.54M
- EPS
- 1.02
- P/E
- 38.71
- Div yield
- 0.00%
More statistics
- Low
- 41.03
- High
- 41.05
- Beta
- -0.25
- Inst. own
- 110.43%
- Dividend
- 0.00
- Earnings
- Jul 30, 2026
Analyst view
Price target (mean) —
Ratings (0m) 22 14 buy · 8 hold · 0 sell
- Strong buy10
- Buy4
- Hold8
- Sell0
- Strong sell0
Recommendation trend
- This month 22
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3175 | -0.49 – -0.16 | -0.33 | +3.8% | 209.89M | +17.6% | 8 |
| Current quarter | -0.3628 | -0.62 – -0.17 | -0.74 | +51.0% | 203.29M | +21.9% | 13 |
| Current quarter | 0.9418 | -0.58 – 1.67 | -0.46 | +304.7% | 409.16M | +107.9% | 11 |
| Current quarter | -0.4703 | -0.60 – -0.27 | -0.2882 | -63.2% | 188.65M | -5.5% | 14 |
| Current quarter | -0.344 | -0.47 – -0.20 | -0.54 | +36.3% | 195.90M | +13.7% | 9 |
| Current quarter | -0.30 | -0.43 – -0.17 | -1.17 | +74.4% | 200.35M | +81.5% | 19 |
| Current quarter | -0.32 | -0.42 – -0.09 | -1.02 | +68.6% | 191.07M | +172.0% | 16 |
| Current quarter | -0.52 | -0.83 – -0.14 | -1.56 | +66.7% | 163.35M | +264.2% | 14 |
| Current quarter | -0.85 | -1.15 – 0.88 | -1.75 | +51.4% | 99.74M | +352.2% | 13 |
| Current quarter | -1.32 | -1.50 – -0.84 | -1.46 | +9.6% | 70.25M | +330.4% | 14 |
| Current quarter | -1.46 | -1.74 – -0.97 | -1.42 | -2.8% | 26.10M | +81.5% | 13 |
| Current quarter | -1.45 | -1.75 – -1.11 | -2.28 | +36.4% | 21.59M | 0.0% | 15 |
| Current quarter | -1.36 | -1.68 – -1.07 | -2.72 | +50.0% | 16.94M | +3288.0% | 15 |
| Current quarter | -1.33 | -1.83 – -1.05 | -2.32 | +42.7% | 14.38M | 0.0% | 14 |
| Current quarter | -1.65 | -1.92 – -1.10 | -1.79 | +7.8% | 11.17M | +1629.1% | 15 |
| Current quarter | -1.69 | -1.97 – -1.42 | -1.57 | -7.6% | 623.00K | 0.0% | 13 |
| Current quarter | -1.62 | -2.01 – -0.97 | -2.29 | +29.3% | 2.27M | 0.0% | 13 |
| Current quarter | -1.58 | -1.85 – -1.22 | -1.10 | -43.6% | 0 | 0.0% | 14 |
| Current quarter | -1.33 | -1.55 – -1.11 | -1.12 | -18.7% | 0 | 0.0% | 13 |
| Current quarter | -1.38 | -1.52 – -1.03 | -0.87 | -58.6% | 0 | 0.0% | 11 |
| Current quarter | -1.01 | -1.11 – -0.91 | -0.64 | -57.8% | 0 | 0.0% | 6 |
| Current quarter | -0.77 | -0.83 – -0.68 | -0.61 | -26.2% | 0 | 0.0% | 6 |
| Current quarter | -0.67 | -0.72 – -0.61 | -0.43 | -55.8% | 0 | 0.0% | 5 |
| Current quarter | -0.69 | -0.78 – -0.63 | -1.37 | +49.6% | 0 | 0.0% | 4 |
| Current quarter | -0.47 | -0.61 – -0.41 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Current quarter | -0.33 | -0.38 – -0.27 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.28 | -0.60 – -0.10 | 1.67 | -116.8% | 219.17M | -52.2% | 8 |
| Current year | -1.17 | -2.19 – -0.38 | 0.20 | -686.9% | 924.86M | -7.9% | 8 |
| Current year | 0.2598 | 0.04 – 0.50 | -1.58 | +116.4% | 1.00B | +28.6% | 11 |
| Current year | -1.71 | -1.92 – -1.56 | -4.45 | +61.5% | 766.26M | +93.2% | 9 |
| Current year | -4.44 | -4.99 – -3.80 | -6.15 | +27.8% | 392.39M | +420.3% | 15 |
| Current year | -6.28 | -7.66 – -5.58 | -8.84 | +29.0% | 77.30M | +16.1% | 14 |
| Current year | -8.77 | -9.49 – -7.63 | -4.59 | -91.1% | 15.02M | -94.0% | 15 |
| Current year | -6.29 | -8.03 – -3.53 | -4.90 | -28.4% | 88.70M | 0.0% | 13 |
| Current year | -4.23 | -4.36 – -4.00 | -2.34 | -80.8% | 0 | 0.0% | 10 |
| Current year | -2.30 | -2.45 – -1.85 | -3.67 | +37.3% | 0 | 0.0% | 5 |
| Current year | -1.07 | -1.62 – -0.51 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next year | -0.3143 | -2.02 – 0.68 | -1.17 | +73.2% | 1.03B | +11.2% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | Initiated | — | Sector Perform |
| Oct 16, 2024 | William Blair | Initiated | — | Outperform |
| Sep 24, 2024 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Sep 23, 2024 | Baird | Maintained | Outperform | Outperform |
| Sep 20, 2024 | Mizuho | Maintained | Neutral | Neutral |
| Sep 20, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 13, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 13, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 9, 2024 | UBS | Maintained | Buy | Buy |
| Aug 9, 2024 | Wedbush | Maintained | Neutral | Neutral |
| Aug 9, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Aug 9, 2024 | Baird | Maintained | Outperform | Outperform |
| Aug 9, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 2, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Aug 2, 2024 | Needham | Reiterated | Buy | Buy |
| Jul 31, 2024 | Jefferies | Maintained | Buy | Buy |
| Jul 26, 2024 | Baird | Maintained | Outperform | Outperform |
| Jul 23, 2024 | Baird | Maintained | Outperform | Outperform |
| Jul 17, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jun 28, 2024 | Baird | Maintained | Outperform | Outperform |
| May 31, 2024 | Piper Sandler | Initiated | — | Neutral |
| May 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 23, 2024 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 8, 2024 | Citigroup | Maintained | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 8, 2024 | UBS | Maintained | Buy | Buy |
| May 8, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 29, 2024 | Mizuho | Maintained | Neutral | Neutral |
| Apr 26, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |